Konstantinos Stravodimos
YOU?
Author Swipe
View article: Urinary peptidomic signatures predict overall and progression-free survival in patients with bladder cancer
Urinary peptidomic signatures predict overall and progression-free survival in patients with bladder cancer Open
Clinicopathologic calculators for bladder cancer moderately predict survival and fail to depict the underlying molecular phenotype. We applied urinary capillary electrophoresis–mass spectrometry (CE–MS) to identify prognostic signatures li…
View article: Magnetic resonance imaging/ultrasound fusion-guided transperineal prostate biopsy: Protocol for a clinic-based surgical technique
Magnetic resonance imaging/ultrasound fusion-guided transperineal prostate biopsy: Protocol for a clinic-based surgical technique Open
Background: Prostate biopsy is a crucial diagnostic tool for detecting clinically significant prostate cancer (csPCa). Traditional transrectal ultrasound (TRUS)-guided biopsy methods are often associated with an increased infection risk of…
View article: Fusion MRI/Ultrasound-Guided Transperineal Biopsy: A Game Changer in Prostate Cancer Diagnosis
Fusion MRI/Ultrasound-Guided Transperineal Biopsy: A Game Changer in Prostate Cancer Diagnosis Open
Background/Objectives: Multiparametric-Magnetic Resonance Imaging(mp-MRI) presents the ability to detect clinically significant cancer, aiming to avoid biopsy if the results are negative or target an abnormal lesion if a suspected lesion o…
View article: Up-regulation of Cuproptosis-related lncRNAS in Patients Receiving Immunotherapy for Metastatic Clear Cell Renal Cell Carcinoma Indicates Progressive Disease
Up-regulation of Cuproptosis-related lncRNAS in Patients Receiving Immunotherapy for Metastatic Clear Cell Renal Cell Carcinoma Indicates Progressive Disease Open
Cuproptosis-related lncRNAs FOXD2-AS1, MINCR, LINC02154 show promise for the prediction of patient response (CB vs. PD) in ICI-based therapeutic schemes in patients with mccRCC.
View article: Endourological Treatment of Hydrocalycosis in a Patient With Kidney Transplantation
Endourological Treatment of Hydrocalycosis in a Patient With Kidney Transplantation Open
View article: CDKN2A copy number alteration in bladder cancer: Integrative analysis in patient-derived xenografts and cancer patients
CDKN2A copy number alteration in bladder cancer: Integrative analysis in patient-derived xenografts and cancer patients Open
View article: 28S rRNA-Derived Fragments Represent an Independent Molecular Predictor of Short-Term Relapse in Prostate Cancer
28S rRNA-Derived Fragments Represent an Independent Molecular Predictor of Short-Term Relapse in Prostate Cancer Open
Prostate cancer (PCa) is a global health concern, being a leading cause of cancer-related mortality among males. Early detection and accurate prognosis are crucial for effective management. This study delves into the diagnostic and prognos…
View article: Distribution of human papillomaviruses (HPV) by geographical area and affected organ in Greece
Distribution of human papillomaviruses (HPV) by geographical area and affected organ in Greece Open
Introduction: Even today we do not have a comprehensive picture of the impact of the virus in Greece and its location at various anatomical sites. Aim: The aim of the study was to investigate and record the impact of HPV infection in the G…
View article: A Giant Oncocytoma in an Elderly Female Patient: A Case Report
A Giant Oncocytoma in an Elderly Female Patient: A Case Report Open
View article: Deregulated Expression of IL-37 in Patients with Bladder Urothelial Cancer: The Diagnostic Potential of the IL-37e Isoform
Deregulated Expression of IL-37 in Patients with Bladder Urothelial Cancer: The Diagnostic Potential of the IL-37e Isoform Open
Cellular and molecular immune components play a crucial role in the development and perpetuation of human malignancies, shaping anti-tumor responses. A novel immune regulator is interleukin-37 (IL-37), already shown to be involved in the i…
View article: Supplementary Table S7 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S7 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S7. Logistic regression analysis to investigate the potential confounding effect of previous supplementary treatment in the classification score of the 106 peptide biomarker panel.
View article: Supplementary Table S5 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S5 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S5. List of all peptides that were included in the peptide biomarker panels for detecting primary and recurrent UBC. For primary UBC, 116 peptide biomarkers were employed and optimized in an SVM-based classifier, using …
View article: Supplementary Table S2 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S2 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S2. Clinical and demographical data for the urine samples (n= 636) from recurrent UBC patients, categorized in the discovery (n=425) and validation phase (n=211). The distribution of the patients which previously receiv…
View article: Data from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Data from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Purpose: Urothelial bladder cancer presents high recurrence rates, mandating continuous monitoring via invasive cystoscopy. The development of noninvasive tests for disease diagnosis and surveillance remains an unmet clinical need. …
View article: Supplementary Table S7 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S7 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S7. Logistic regression analysis to investigate the potential confounding effect of previous supplementary treatment in the classification score of the 106 peptide biomarker panel.
View article: Data from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Data from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Purpose: Urothelial bladder cancer presents high recurrence rates, mandating continuous monitoring via invasive cystoscopy. The development of noninvasive tests for disease diagnosis and surveillance remains an unmet clinical need. …
View article: Supplementary Table S5 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S5 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S5. List of all peptides that were included in the peptide biomarker panels for detecting primary and recurrent UBC. For primary UBC, 116 peptide biomarkers were employed and optimized in an SVM-based classifier, using …
View article: Supplementary Table S6 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S6 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S6. Multivariate analysis for investigating the comparative performance of the biomarker classifier and cytology for detecting recurrence. Of the 211 subjects that were included in the validation phase, voided urinary c…
View article: Supplementary Table S4 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S4 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S4. Table summarizing the significant biomarkers that were revealed after statistical analysis between recurrent UBC cases (n=109) and negative for recurrence controls (n=316), using Wilcoxon test. The significant bioma…
View article: Supplementary Table S6 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S6 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S6. Multivariate analysis for investigating the comparative performance of the biomarker classifier and cytology for detecting recurrence. Of the 211 subjects that were included in the validation phase, voided urinary c…
View article: Supplementary Table S1 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S1 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S1. Clinical and demographical data for the full list of 721 samples from patients with primary UBC, separated in 451 urine samples to be included in the discovery phase and 270 urine samples to be included in the valid…
View article: Supplementary Table S8 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S8 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S8. Correlation analysis of the 116 peptide biomarkers with disease stage and grade and performance of peptide classifiers in detecting NMIBC and MIBC.
View article: Supplementary Table S3 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S3 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S3. Shortlist of significant biomarkers, as derived based on statistical analysis between primary UBC cases (n=341) and urological controls (n=110) - including negative after cystoscopy samples, samples from patients wi…
View article: Supplementary Table S2 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S2 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S2. Clinical and demographical data for the urine samples (n= 636) from recurrent UBC patients, categorized in the discovery (n=425) and validation phase (n=211). The distribution of the patients which previously receiv…
View article: Data from Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics
Data from Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics Open
Purpose: Minimally invasive methods of predicting the risk of muscle-invasive urothelial bladder carcinoma may expedite appropriate therapy and reduce morbidity and cost.Experimental Design: Here, capillary electrophoresis co…
View article: Supplementary Table S1 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S1 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S1. Clinical and demographical data for the full list of 721 samples from patients with primary UBC, separated in 451 urine samples to be included in the discovery phase and 270 urine samples to be included in the valid…
View article: Supplementary Table S3 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S3 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S3. Shortlist of significant biomarkers, as derived based on statistical analysis between primary UBC cases (n=341) and urological controls (n=110) - including negative after cystoscopy samples, samples from patients wi…
View article: Supplementary Table S8 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S8 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S8. Correlation analysis of the 116 peptide biomarkers with disease stage and grade and performance of peptide classifiers in detecting NMIBC and MIBC.
View article: Supplementary Data from Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics
Supplementary Data from Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics Open
Supplementary Data from Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics
View article: Supplementary Table S4 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Supplementary Table S4 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study Open
Supplementary Table S4. Table summarizing the significant biomarkers that were revealed after statistical analysis between recurrent UBC cases (n=109) and negative for recurrence controls (n=316), using Wilcoxon test. The significant bioma…